Profile data is unavailable for this security.
About the company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
- Revenue in USD (TTM)181.74m
- Net income in USD-296.81m
- Incorporated2001
- Employees525.00
- LocationArrowhead Pharmaceuticals Inc177 E Colorado Blvd, Suite 700PASADENA 91105United StatesUSA
- Phone+1 (626) 696-4702
- Fax+1 (626) 304-3401
- Websitehttps://arrowheadpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neogen Corp | 929.24m | 1.57m | 2.67bn | 2.64k | 1,707.35 | 0.8475 | 22.62 | 2.87 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| ACADIA Pharmaceuticals Inc | 726.44m | -61.29m | 2.76bn | 597.00 | -- | 6.38 | -- | 3.80 | -0.3774 | -0.3774 | 4.43 | 2.62 | 1.09 | 1.96 | 9.05 | 1,216,812.00 | -9.17 | -27.50 | -12.81 | -32.73 | 94.27 | 95.62 | -8.44 | -38.35 | 2.28 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.76bn | 50.00 | -- | 5.28 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 2.79bn | 497.00 | -- | 7.73 | -- | 11.20 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Arcellx Inc | 110.32m | -70.69m | 2.90bn | 130.00 | -- | 5.86 | -- | 26.30 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.91bn | 91.00 | -- | 6.33 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Ideaya Biosciences Inc | 23.38m | -112.96m | 2.91bn | 124.00 | -- | 4.09 | -- | 124.42 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Azenta Inc | 641.02m | -17.37m | 2.93bn | 3.50k | -- | 1.20 | 41.92 | 4.57 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 2.95bn | 525.00 | -- | 15.94 | -- | 16.21 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.10bn | 251.00 | -- | 3.34 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.16bn | 517.00 | -- | 19.63 | -- | 7.92 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 28 Mar 2024 | 12.40m | 10.01% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 12.08m | 9.75% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.83m | 5.51% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.35m | 2.70% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.33m | 1.88% |
| Invesco Advisers, Inc.as of 31 Dec 2023 | 1.86m | 1.50% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 1.60m | 1.29% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2023 | 1.42m | 1.15% |
| Slate Path Capital LPas of 31 Dec 2023 | 1.33m | 1.07% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.32m | 1.07% |
